Sofosbuvir
- Generic Name
- Sofosbuvir
- Brand Names
- Epclusa, Harvoni, Sovaldi, Vosevi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FN3O9P
- CAS Number
- 1190307-88-0
- Unique Ingredient Identifier
- WJ6CA3ZU8B
- Background
Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, ...
- Indication
Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.
...
- Associated Conditions
- Chronic Hepatitis C - Genotype 3, Chronic Hepatitis C Genotype 1, Chronic Hepatitis C Virus (HCV) Infection, Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 2, Chronic hepatitis C genotype 5, Genotype 4 Chronic Hepatitis C, Genotype 6 chronic hepatitis C infection
- Associated Therapies
- -
A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02556086
- Locations
- 🇫🇷
Local Institution, Pessac, France
A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02551861
- Locations
- 🇫🇷
Local Institution, Vandoeuvre Les Nancy, France
Directly Observed Therapy for HCV in Chennai, India
- Conditions
- Interventions
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 50
- Registration Number
- NCT02541409
- Locations
- 🇮🇳
YR Gaitonde Centre for AIDS Research and Education, Chennai, Tamil Nadu, India
Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 71
- Registration Number
- NCT02528461
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus C, Denmark
Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Stanford University
- Registration Number
- NCT02485080
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Yale University Medical Center, New Haven, Connecticut, United States
SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Humanity and Health Research Centre
- Target Recruit Count
- 106
- Registration Number
- NCT02473211
- Locations
- 🇨🇳
Humanity and Health GI and Liver Centre, Hong Kong, Hong Kong, China
🇨🇳Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital, Beijing, Beijing, China
Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-03-19
- Target Recruit Count
- 72
- Registration Number
- NCT02468648
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa
- Conditions
- Interventions
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 120
- Registration Number
- NCT02405013
- Locations
- 🇨🇮
CHU de Youpougon - Service de Gastro-entéro-hépatologie, Abidjan, Côte D'Ivoire
🇨🇲Clinique de la Cathédrale, Yaoundé, Cameroon
🇸🇳CHU Fann, Service des Maladies Infectieuses, Dakar, Senegal
A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
- Conditions
- Interventions
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2016-04-07
- Lead Sponsor
- Pharco Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT02371408
- Locations
- 🇪🇬
National Liver Institute, Menoufiya, Egypt
🇪🇬Al-Qahira Al-Fatimeya MoH Hospital, Cairo, Egypt
🇪🇬Kasr El Aini Viral Hepatitis Center, Cairo, Egypt
Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)
- Conditions
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 257
- Registration Number
- NCT02358044
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.